Evidence map›Paper›PMID 37651112›Full record

ArticleInvestigative ophthalmology & visual science2023

Upregulation of Epac1 Promotes Pericyte Loss by Inducing Mitochondrial Fission, Reactive Oxygen Species Production, and Apoptosis.

Wenli Yang, Fan Xia, Fang Mei, Shuizhen Shi, William G Robichaux, Wei Lin, Wenbo Zhang, Hua Liu, Xiaodong Cheng

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wenli YangDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas, United States.
Fan XiaDepartment of Ophthalmology & Visual Sciences, University of Texas Medical Branch, Galveston, Texas, United States.
Fang MeiDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas, United States.
Shuizhen ShiDepartment of Ophthalmology & Visual Sciences, University of Texas Medical Branch, Galveston, Texas, United States.
William G RobichauxDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas, United States.
Wei LinDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas, United States.
Wenbo ZhangDepartment of Ophthalmology & Visual Sciences, University of Texas Medical Branch, Galveston, Texas, United States.
Hua LiuDepartment of Ophthalmology & Visual Sciences, University of Texas Medical Branch, Galveston, Texas, United States.
Xiaodong ChengDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas, United States.
The University of Texas Health Science Center at Houston · USThe University of Texas Medical Branch at Galveston · US

Funding

Mechanisms of Retinal Neuronal InjuryR01EY022694 · NEI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ZHANG, WENBO · 2012 to 2021
$3.8M
Epac1 as a novel therapeutic target for diabetic retinopathyR01EY033319 · NEI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI XIAODONG CHENG, Hua Liu · 2022 to 2026
$2.6M
NEI NIH HHS R01 EY022694NEI NIH HHS R01 EY033319
6 · The paper itself

Abstract

Purpose: The pathogenic mechanisms behind the development of ischemic retinopathy are complex and poorly understood. This study investigates the involvement of exchange protein directly activated by cAMP (Epac)1 signaling in pericyte injury during ischemic retinopathy, including diabetic retinopathy, a disease that threatens vision. Methods: Mouse models of retinal ischemia-reperfusion injury and type 1 diabetes induced by streptozotocin were used to investigate the pathogenesis of these diseases. The roles of Epac1 signaling in the pathogenesis of ischemic retinopathy were determined by an Epac1 knockout mouse model. The cellular and molecular mechanisms of Epac1-mediated pericyte dysfunction in response to high glucose were investigated by specific modulation of Epac1 activity in primary human retinal pericytes using Epac1-specific RNA interference and a pharmacological inhibitor. Results: Ischemic injury or diabetes-induced retinal capillary degeneration were associated with an increased expression of Epac1 in the mouse retinal vasculature, including both endothelial cells and pericytes. Genetic deletion of Epac1 protected ischemic injury-induced pericyte loss and capillary degeneration in the mouse retina. Furthermore, high glucose-induced Epac1 expression in retinal pericytes was accompanied by increased Drp1 phosphorylation, mitochondrial fission, reactive oxygen species production, and caspase 3 activation. Inhibition of Epac1 via RNA interference or pharmacological approaches blocked high glucose-mediated mitochondrial dysfunction and caspase 3 activation. Conclusions: Our study reveals an important role of Epac1 signaling in mitochondrial dynamics, reactive oxygen species production, and apoptosis in retinal pericytes and identifies Epac1 as a therapeutic target for treating ischemic retinopathy.

Indexed as

Guanine Nucleotide Exchange FactorsPericytesRetinal DegenerationAnimalsApoptosisCaspase 3Endothelial CellsGlucoseHumansMiceMitochondrial DynamicsReactive Oxygen SpeciesUp-RegulationCaspase 3Epac protein, mouseGlucoseGuanine Nucleotide Exchange FactorsReactive Oxygen Species

Identifiers

PMID37651112
PMCPMC10476449
OpenAlexW4386305665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.